卡德纳尔疗法公司美股招股说明书(2025-12-23版)

Up to $1,770,028 Shares of Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated March 20, 2024 (the “BaseProspectus”), filed with the Securities and Exchange Commission (the “SEC”) as part of our registration statement on Form S-3 (FileNo. 333-277835), which was declared effective by the SEC on March 20, 2024, as previously supplemented by our prospectussupplements, dated December 20, 2024, April 17, 2025, November 18, 2025 and December 15, 2025 (collectively the “PriorProspectus Supplements” and, together with the Base Prospectus, the “Prior Prospectus”), initially relating to the offer and sale of upto $5,143,730 of shares of our common stock, par value $0.001 per share (the “Common Stock”), which was increased by $2,512,330of shares of Common Stock pursuant to the prospectus supplement, dated December 20, 2024, and was subsequently increased by$2,169,272 of shares of Common Stock pursuant to the prospectus supplement, dated April 17, 2025, and further increased by$3,438,062 of shares of Common Stock pursuant to the prospectus supplement, dated November 18, 2025, and was decreased to$569,717 of shares of Common Stock pursuant to the prospectus supplement, dated December 15, 2025 (the “December ProspectusSupplement”). Sales under the Prior Prospectus Supplements were made pursuant to that certain At the Market Offering Agreement, We have sold an aggregate of $10,005,300 of shares of Common Stock as of the date of this prospectus supplement pursuant to thesales agreement and the Base Prospectus, as supplemented by the Prior Prospectus Supplements. The Common Stock is listed on the Nasdaq Capital Market under the symbol “CVKD.” On December22, 2025, the last reported saleprice of the Common Stock on the Nasdaq Capital Market was $7.535 per share. The purpose of this prospectus supplement is to increase the amount available under the December Prospectus Supplement to up to$1,770,028 of shares of Common Stock. Sales of shares of Common Stock, if any, under this prospectus supplement will be made in sales deemed to be an “at the marketoffering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), includingsales made directly on or through the Nasdaq Stock Market (“Nasdaq”) or any other existing trading market in the United States forCommon Stock, sales made to or through a market maker other than on an exchange or otherwise, directly to Wainwright as principal,in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or inany other method permitted by law. Wainwright is not required to sell any specific number or dollar amount of shares but will use its As sales agent, Wainwright will be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share soldunder the sales agreement. In connection with the sale of Common Stock on our behalf, Wainwright will be deemed to be an“underwriter” within the meaning of the Securities Act and the compensation of Wainwright will be deemed to be underwriting As of the date of this prospectus supplement, the aggregate market value of our outstanding shares of Common Stock held by non-affiliates, or the public float, was $26,645,228, which was calculated based on 1,885,120 outstanding shares of Common Stock held bynon-affiliates at a price of $14.1345 per share of Common Stock, the closing price of the Common Stock on October 24, 2025, asreported on the Nasdaq Capital Market. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell shares of CommonStock pursuant to this prospectus supplement with a value of more than one-third of the aggregate market value of Common Stock Investing in our Common Stock involves a high degree of risk. Before making an investment decision, please read theinformation under the heading “Risk Factors” on pages S-6, S-5, S-4 and S-4 of each of the Prior Prospectus Supplementsdated December 20, 2024, April 17, 2025, November 18, 2025 and December 15, 2025, respectively, and page 6 of the Base Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of the Prior Prospectus, this prospectus supplement or the accompanying The date of this prospectus supplement is December23, 2025.